Latest Breaking News On - Pharmaceuticals price performance - Page 6 : vimarsana.com

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $21 00 at Mizuho

ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $21 00 at Mizuho
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesJames kiharaStephen davisPharmaceuticals price performanceChina universal asset management coSecurities exchange commissionQuest partnersPharmaceuticals incLegato capital managementRoyal bankPharmaceuticals dailyNeedham companyAcadia pharmaceuticalsHeadlands technologiesGet free reportExchange commission

Oppenheimer Reiterates Market Perform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Oppenheimer Reiterates Market Perform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesMarkc schneyerStephen davisRoyal bankPharmaceuticals incSg americas securitiesSecurities exchange commissionPharmaceuticals price performanceNeedham companyCapital partnersSwiss national bankHeadlands technologiesAcadia pharmaceuticalsPharmaceuticals dailySei investments coGet free report

HC Wainwright Reiterates Buy Rating for ASLAN Pharmaceuticals (NASDAQ:ASLN)

HC Wainwright reiterated their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN – Free Report) in a report released on Friday, Benzinga reports. The brokerage currently has a $9.00 price target on the stock. Separately, Piper Sandler reaffirmed an overweight rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN […]

Piper sandlerPharmaceuticals price performancePharmaceuticals dailyFree reportGet free reportAslan pharmaceuticalsNasdaq aslnReiterated ratingHc wainwright

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) CEO Stephen Davis Sells 11,427 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) CEO Stephen Davis sold 11,427 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $193,573.38. Following the transaction, the chief executive officer now owns 155,231 shares of the company’s […]

Sakhalinskaya oblastUnited statesRobertw bairdStephen davisPharmaceuticals price performancePharmaceuticals company profilePharmaceuticals dailyNorges bankEventide asset managementAcadia pharmaceuticals incPharmaceuticals incMg investment management ltdRoyal bankFred alger managementGet free reportAlger management

ACADIA Pharmaceuticals (NASDAQ:ACAD) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $37.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on ACAD. Royal Bank of Canada decreased […]

United statesRobertw bairdMarkc schneyerBrendan teehanPharmaceuticals incCharles schwab investment management incSecurities exchange commissionRoyal bankJpmorgan chase coMutual of america capital managementNorthern trust corpCantor fitzgeraldPharmaceuticals dailyPharmaceuticals price performanceQube research technologies ltdMorgan stanley